Bloomios, Inc.

Equities

BLMS

US0948571098

Healthcare Facilities & Services

Market Closed - OTC Markets 12:52:00 2024-05-13 pm EDT 5-day change 1st Jan Change
0.0006 USD 0.00% Intraday chart for Bloomios, Inc. -33.33% -80.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Involuntary Petition Filed Against Bloomios, Inc. CI
Bloomios, Inc. Ceases Manufacturing At the Facility and Terminated All Employees CI
Bloomios, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bloomios, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Bloomios, Inc. Provides Revenue Guidance for the Second Quarter of 2023 CI
Bloomios, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bloomios, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bloomios, Inc. Auditor Raises 'Going Concern' Doubt CI
Bloomios, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Bloomios, Inc. announced that it has received $0.852941 million in funding CI
Bloomios, Inc. Closes on an Offering of the Debentures CI
Bloomios, Inc. acquired Infusionz, LLC from Upexi, Inc. for $23.5 million. CI
Bloomios, Inc. announced that it has received $2.083958 million in funding CI
Bloomios, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Bloomios, Inc. to Develop and Produce New Range of Private-Label Products Utilizing, Ashwagandha, Melatonin, Kratom, Lion's Mane, Valerian Root, Reishi Mushroom and Other Natural Ingredients CI
Bloomios Expands Production Capacity by 300%, Setting Stage for Strong Growth in 2022 CI
Bloomios, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Earnings Flash (BLMS) BLOOMIOS Posts Q4 Revenue $1.7M MT
Bloomios, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Bloomios, Inc. Auditor Raises 'Going Concern' Doubt CI
Bloomios, Inc. Announces Selection as the Exclusive Cannabidiol Product Manufacturer for DRYWORLD CI
Bloomios, Inc. announced that it has received $0.25 million in funding CI
Bloomios, Inc. announced that it expects to receive $0.25 million in funding CI
Bloomios, Inc. Provides Earnings Guidance for the Year 2021 CI
Bloomios, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Chart Bloomios, Inc.
More charts
Bloomios, Inc. manufactures, markets, and distributes hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States, through its wholly owned subsidiary, Bloomios Private Label (BPL). BPL is engaged in the manufacturing, processing, sourcing and distribution of hemp-derived, nootropic and nutraceutical products to wholesalers and retailers. The Company manufactures hemp infused products ranging from human edibles, pet edibles, liquid consumables such as tinctures and shots, topicals, and smokable hemp. It provides support at each step from custom formulation, order fulfillment, and brand development. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages and pet treats. It offers its private-label and white-label customers a collections of customizable hemp products that includes over 80 products across seven categories in addition to custom formulation and manufacturing services.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BLMS Stock
  4. News Bloomios, Inc.
  5. Earnings Flash (BLMS) BLOOMIOS Posts Q4 Revenue $1.7M
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW